Grant Award Details
Safety “Clinical Trial” of the Cardiac Liability of COVID19 Polytherapy
- The objective is to validate a stem cell-based microphysiological system (MPS) for predicting cardiac toxicity, including modeling drug-drug interactions in polytherapy for the treatment of SARS-CoV-2 in patients with diverse backgrounds
Human Stem Cell Use:
Under a previous CIRM Award, we developed a stem cell based “heart on a chip” model for predicting toxic responses to drugs. We have now applied this model towards understanding potential toxicities of drugs used for COVID19 treatment and over the past 12 months, have successfully demonstrated a correlation between what can be detected on our chip in the laboratory vs. real outcomes in the clinic. We will continue to build off this effort by screening for potential risks of novel combinations of frontline therapies for COVID19.
Grant Application Details
- Safety “Clinical Trial” of the Cardiac Liability of COVID19 Polytherapy
Statement of Benefit to California: